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Between November, 1962 and August, 1975, 668 kidney 
transplants were done in 556 consecutive patients at Denver, 
Colorado. The Denver experience has been divided into 7 pe-
riods of time, according to the conditions of care during each 
period. The results in related transplantation have changed 
little during the decade beginning in 1966. The results in unre-
lated transplantation have not materially changed since 1968. 
The long-term patient survival after related transplantation 
has been better than after cadaver transplantation. The re-
sults of transplantation in 57 children ages 3 to 18 years have 
been slightly better than the results of adult transplantation. 
The outcome of kidney transplantation and the feasibility 
of improving this therapy with present techniques are limited 
by our inability to accurately match each patient with the im-
munologically best donor and by our inability to precisely 
control the immune system rf the recipient. Rejection is still 
the main reason for graft loss, and sepsis remains the main 
cause of patient mortality. More specific and less toxic means 
of achieving graft acceptance are needed before a higher level 
of patient sen ice can be realized. However, even with the 
tools now available, thousands of recipients throughout the 
world have been returned to useful lives. 
Approximately 25.000 kidney transplants were car-
ried out and reported to the ACS/NI H kidney trans-
plant registry prior to the dissolution of this organi-
zation in the summer of 1976. During the almost 13-
year period from November. 1962 until August, 1975, 
668 kidney transplants were done at the University of 
Colorado Medical Center and the Denver Veterans 
Supported by research projects M RIS 8118-0 I and 7227-
01 from the Veterans Administration: bv United States 
Public Health Service Grants AM-17260 'and AM-07772: 
and by Grants RR-00051 and RR-00069 from the General 
Clinical Research Centers Program of the Division of Re-
search Resources. National Institutes of Health. 
R('prilll rt'I.{II(·sts: Richard Wei!. III, M.D .. Box C-305. 
University of Colorado Medical Center. 4200 East Ninth 
Avenue. Denver. Colorado 80262. U.S.A. 
145 
Administration Hospital. Follow-up data have been 
obtained on each of the 556 consecutive patients 
treated during this interval. with a minimum period 
of 1 year of post-transplant observation in the most 
recent cases. The Denver experience is presented to il-
lustrate the development of kidney transplantation 
and as an example of current trends in the field~ 
Methods: Denver Conditions of Care 
Case Material and Immunosuppression 
The Denver kidney transplantation experience be-
tween 1962 and 1975 has been divided into seven peri-
ods according to the conditions of care rendered dur-
ing these times. The characteristics of these periods 
are summarized in Table 1. Prior to March. \968. 
when series 4 was started. certain high-risk cases were 
advised not to undergo transplantation: since 1968 all 
patients who have desired transplantation have been 
accepted. except for very rare instances where it was 
thought that the patient could probably not tolerate 
anesthesia or immunosuppression. I n recent years 
transplantation has been carried out with increasing 
frequency in patients with advanced age. coronary ar-
tery disease. diabetes mellitus. and other systemic dis-
orders. 
Between November. 1962 and April. 1966 (series I 
and 2), immunosuppression consisted of prednisone 
and azathioprine. In June, 1966 (series 3). antilym-
phocyte globulin (ALG) was added to azathioprine 
and prednisone. The same conditions applied in 
series 4. Between March. 1971 and August, 1972 
(series 5). cyclophosphamide was substituted for 
azathioprine in the triple-drug immunosuppressive 
program: since August. 1972 azathioprine rather than 
cyclophosphamide has been used because cyclophos-
phamide was found to have no advantage over 
azathioprine. 
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qabl~ I. Denver kidney transplantation 1962-1975 
No. of cases 
Follow·up 
Series Related Unrelated Dates (years) Characteristics of care 
I 46 18 November. 1962-March. 1964 12IfJ-13J!4 Azathioprine/prednisone: good risk 
2 25 23 October. 1964-April, 1966 101/1-11% Azathioprine/prednisone + typing: . 
good risk 
3 60 17 June, 1966-February, 1968 811.1-101/. Azathioprine/prednisone/ A LG: 
good risk 
4 122 15 March. 1968-March. 1971 R1f~-Ufh Azathioprine/prednisone/ A LG: all 
risk 
5 44 28 March. 1971-A ugust. 1972 4-5 1/2 Cyclophosphamide/prednisone/ 
ALG: all risk 
6 65 49 August. 1972-August. 1974 2-4 Azathioprine/prednisone/ A LG: all 
risk 
7 27 17 September. 1974-August, 1975 1-2 Azathioprine/prednisone/ A LG: all 
Donor Selection 
From 1962 until late 1965 volunteer living unrelated 
donors were used in some cases; since 1965 all unre-
lated kidneys have been obtained from cadaver do-
nors: During the period October, 1964 until April, 
1966 (series 2), related and cadaver kidney recipients 
were selected according to the results of human leu-
kocyte antigen (HLA) matching; since 1966 HLA 
matching has been used mainly for the selection of 
HLA-identical sibling donors. During almost all of 
the 14-year period. an effort has been made to pre-
vent hyperacute graft rejection by the use of a sensi-
tive direct cytotoxicity crossmatch test. Recently, do-
nor lymph node cells have been used as a target cell in 
risk 
most cases, and two samples of recipient's serum-
the most current serum sample and the sample with 
the highest percentage of antibodies against a ran-
dom panel of lymphocytes-have been tested for the 
presence o~ preformed antibodies. 
Cadaver Kidney Preservation 
From 1962 to 1968. cadaver kidneys were harvested 
after cardiac standstill or from heart-beating cada-
vers or from cadaver donors whose circulation was 
being maintained by cardiopulmonary bypass. The 
removed organs were further cooled by infusion with 
chilled electrolyte solutions with or without low mo-
lecular weight dextran. From 1968 to 1971. some of 
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Fig. I. Life survival curves of patients 
treated with primary related homografts 
during five intervals from 1962 to the 
summer of 1972. Arrows show time of . I 
2 3 4 5 6 78 9 10 II 12 13 minimum follow-up. Description of I 
groups is in Table I. (By permission of I,· 
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Table 2. Patient survival after primary related transplantation 1962-1975 
Percent survival 
No. of 
Series cases I year 2 years 4 years 8 years 10 years 
1 46 67 65 61 57 
2 25 64 64 52 40 
3 60 92 88 78 67 
4 122 76 73 68 
5 44 86 80 74 
6 65 77 75 
7 27 89 
the cadaver kidneys were stored in a hyperbaric oxy-
gen chamber. From 1971 through 1975, cadaver kid-
neys were preserved by Belzer's machine pulsatile 
perfusion method using cryoprecipitated plasma. 
Since the beginning of 1976, cadaver kidneys which 
were expected to be reimplanted within 24 hours after 
removal from the donor have been stored in modified 
Collins-2 solution (Travenol!Y), without procaine, at 
4°C. 
Results 
Related Transplants 
Patient survival after primary related trans-
plantation has not improved since 1966 (Figure 1, 
Table 2). Patient survival 2 years after transplants 
done between 1962 and 1966 was 65%; in cases done 
between 1966 and 1974, the 2-year patient SUI vival 
ranged from 73 to 88%. I n fact, patient survival was 
less in subsequent series than in the cases .done be-
tween 1966 and 1968, the last period when only 
"good-risk" patients were accepted. This decline in 
patient survival is probably attributable to a progres-
sively more bold approach to recipient selection. 
The durability of primary related grafts is iIIus-
. trated by the high percentage of survivors from the 
1962 to 1964 patients (series 1) whose original grafts 
are still functioning (Table 3). Of the original group 
52 
40 
of 46 patients transplanted 12 to 14 years ago, 22 
(48%) are still living, and 18 of these 22 patients 
(82%) have functioning original grafts. Of the 22 cur-
rent survivors, 3 have had successful retransplanta-
tion, and I patient is back on dialysis after II years of 
function of the original graft, which was donated by a 
cousin and eventually was lost because of chronic re-
jection. Retransplantation has not yet been carried 
out in this patient because of the presence of multiple 
-~ low-grade skin neoplasms, which have been regress-
ing steadily since discontinuation of immunosuppres-
sion, and because of the development of preformed 
cytotoxic antibodies associated with resumption of 
dialysis and a need for blood transfusions. 
Although the risks of retransplantation are higher 
than with primary transplantation [I], our patients 
have been reluctant to return to chronic hemodialysis 
after experiencing the rehabilitation which can be 
provided by a successfully functioning transplant, 
and most of our patients have been retransplanted re-
peatedly until a successful graft could be obtained. Of 
the entire group of 229 survivors after primary re-
lated transplants from series I through 6, only 10 
(4%) are currently on dialysis, and some of these 
patients are waiting for retransplantation. Of the 22 
survivors in the most recent series 7, a total of 6 are 
now on dialysis and all are hoping to be retrans-
planted, but high titers of preformed antibodies have 
prevented us from carrying out this treatment to date. 
Table 3. Graft survival after primary related transplantation 1962-1975 
Functioning 
Time Present original Successful On 
Series following survivors· graft retransplantation dialysis 
1 12'/)-133,4 22/46 (48%) 18 3 1 
2 10 1f3- I Jl/. 10/25 (40%) 7 2 I 
3 . 8'/2- lOll. 40/60 (67%) 30 8 2 
4 51 l-8'h 75/122 (61%) 67 6 2 
5 4 
- 5'h 33/44 (75%) 28 4 I 
6 2-4 49/65 (75%) 40 6 3 
7 1-2 22/27 (81%) 16 0 6 
• July. 1976. 
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Unrelated Transplants 
Volunteer living unrelated donors have not been 
used since 1965 because with rare exceptions such do-
nors offer the patient no significant advantage over a 
cadaver donor. The long-term patient survival after 
primary unrelated transplantation (Figure 2) was dis-
tinctly lower than after primary related trans-
plantation (Figure I). In series I and 2 the IO-year 
patient survival after unrelated transplantation was 
12% (Table 4). compared with 48% (Table 2) after re- -
lated transplantation. However, in the more recently 
treated cases since March. 1968 (series 4 through 7), 
the patient survival following unrelated trans-
plantation is not significantly different from the re-
sults after related transplantation; this improvement 
in patient survival followed our recognition between 
1966 and 1968 that excessive immunosuppression in 
an effort to save a cadaver graft represents an unrea-
sonably high risk to the life of the patient. Since 1968. 
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Fig. 2. Life survival curves after trans-
plantation of nonrelated kidneys during 
the same five time periods as in Fig. 1. 
Description of groups is in Table I. (By 
permission of Transplantation Pro-
ceedings ). 
cadaver graf~s which have demonstrated a repeated 
and relentless propensity for rejection have been 
abandoned. 
I n spite of this willingness to abandon immunolog-
ically difficult cadaver grafts, an aggressive attitude 
toward retransplantation has made it possible to pro-
vide most of the surviving patients with a functioning 
graft (Table 5). Of the 38 surviving patients who re-
ceived primary unrelated grafts between 1962 and 
August. 1972 (series I through 5), only 4 (I1%) are 
back on dialysis. Of the 46 survivors from series 6 and 
7. a total of II are currently on dialysis. but almost al\ 
of these patients are waiting for retransplantation. 
Transplantation in Children 
The results of pediatric kidney transplantation in 
Denver were brought up to date several months ago 
and are comparable to the results of adult kidney 
transplantation [2]. Of 57 children (67%), 35 were 
Table 4. Patient survival after primary unrelated transplantation 1962-1975 '. 
Percent survival 
No. of 
Series cases I year 2 years 4 years 8 years 10 years 
1 18 33 22 17 11 II 
2 23 52 43 30 17 13 
3 17 82 76 41 29 
4 15 80 80 80 
5 28 75 75 61 
6 49 82 71 
7 17 94 r . : 
; 
i 
d ; , 
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Table 5. Graft survival after primary unrelated transplantation 1962-1975 
Functioning 
Time Present original Successful On 
Series following survivors graft retransplantation dialysis 
I 121J1-13 J/4 2/18 (11%) 1 1 
2 101,12-11% 3/23 (13%) 2 0 
3 81,12-101/. 5/17 (29%) 4 I 
4 51,12- 8Y.! 11/15 (73%) 4 5 
5 4- 51f2 17/28(61%) II 5 
6 2- 4 32/49 (65%) 20 6 
7 1- 2 14/17 (82%) 8 I 
• July. 1976. 
alive 6 to 13 years after original transplantation. The 
patient survival was the same for recipients of related 
and unrelated grafts. In all, 10 of the 35 surviving 
patients have been retransplanted. In spite of the bur-
dens imposed on these children by their illness, trans-
plantation. and immunosuppression, most of them 
were able to develop into well-adjusted young adults. 
One 23-year-old woman who received a transplant 13 
years ago from her mother married a transplant sur-
geon. 
Causes of Late Death 
Of the 326 patients transplanted more than 5 years 
ago (series I through 4), 24 died more than 5 years af-
ter the original kidney transplant. Nine of these 24 
patients had undergone retransplantation; 16 died 
with adequately functioning original grafts (Table 6). 
Infection, the leading cause of early post-trans-
plant death [3], was also the major cause of late 
death. There were 6 deaths from pneumonia and 2 
deaths from disseminated cytomegalovirus: The role 
of viral infection in the 4 deaths from liver failure is 
uncertain, but probably viral hepatitis was contrib-
utory in at least some of these cases. Therefore, half 
( 12/24) of the late deaths may have been related to 
. infection. Five deaths were due to cardiovascular dis-
ease (3 mesenteric vascular occlusions, 2 coronary oc-
clusions). The remaining 7 deaths were due to varied 
causes (3 suicides, 2 colon perforations, I hyperpa-
rathyroidism, I cancer). The man who died of cancer 
more than 5 years after transplantation had multiple 
squamous cell epitheliomas of the skin of the head 
and neck, one of which recurred on the external ear 
and eventually metastasized to liver and bone. in 
spite of re-excisions. radical neck dissection. and dras-
tic reduction of immunosuppression. The risks of 
cancer under immunosuppression will be discussed 
helow. 
Discussion 
It is clear from the Denver kidney transplantation 
experience that the results with this treatment have 
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improved little during the last decade. The patient 
and graft survival of patients receiving their grafts in 
recent years differ remarkably little from the results 
obtained by patients transplanted in 1966 (Tables 2 
through 5). During the last decade a great deal has 
been done to try to improve the results of kidney 
transplantation. but there has been no advance in 
knowledge which could be translated into a major 
therapeutic advantage for the patients. Nevertheless, 
it is appropriate to examine the current status of the 
central issues in the field. 
H is/ocompatibility M a/ching 
The ABO blood group antigens are expressed on 
kidney cells, and kidney transplantation in the pres-
ence of donor-recipient ABO incompatibility prob-
ably carries more than a 50% likelihood of early irre-
versible graft rejection [5]. The Rh system is not im-
portant in organ transplantation. 
The histocompatibility test which carries the great-
est predictive value is the direct cross match. which 
identifies preformed antibodies (mostly cytotoxic) in 
the recipient's serum against antigens of the donor. 
The donor target cell is usually a lymph node Iym-
Table 6. Causes of late death more than 5 years after 
primary kidney transplantation 
No. of patients 
No. of with adequate ante-
Causes of death patients mortem kidney function 
Pneumonia 6 4 
Liver failure 4 4 
Mesenteric vascular 
occlusion 3 2 
Suicide 3 1 
Disseminated CMV 
infection 2 I 
Coronary occlusion 2 2 
Colon perforation 2 I 
Cancer I 
Hyperparathyroidism 
and skin gangrene 0 
Total 24 16 
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phocyte. but peripheral blood lymphocytes or kidney 
cells obtained by biopsy can also be used [6]. If pre-
formed antibodies against a donor are detected in a 
recipient by this test. transplantation from that donor 
to that recipient carries approximately a 75% likeli-
hood of early irreversible rejection [7]. and a different 
donor is therefore sought for the patient. 
In 1964. H LA typing began to be used clinically for 
donor selection in Denver. This serologically defined 
system initially appeared to hold great promise for 
the identification of the optimal organ donor for each 
patient. In Denver HLA typing was used regularly 
for donor selection during the 1964 to 1966 period 
(series 2). and the results of transplantation were not 
significantly improved by this tool. H LA typing has 
been done for all Denver cases since then. but since 
1966 the results have been used as a selection in-
strument only to identify perfectly matched sibling 
donors. In the United States HLA typing has had 
limited value for the selection of cadaver and non-
sibling related donors [3], although in Europe better 
correlations between HLA match and graft survival 
have been claimed by some [8]. 
Lymphocyte-defined histocompatibility testing 
similarly has had little impact on the results ofkidney 
transplantation. Donor and recipient lymphocyte 
stimulation in mixed lymphocyte culture (M LC). 
with or without mitomycin inhibition of donor or re-
cipient cells. has had at least some degree of correla-
tion with graft outcome in many reports [9, 10]. but 
the test as usually done requires about 5 days for its 
completion and is. therefore. of only retrospective 
value for cadaver transplantation since organ preser-
vation is at present not feasible for this length of time. 
A more rapid MLC test has been developed [II]. but 
its value is not yet established. 
It remains to be proven that matching a cadaver 
organ donor with a large pool of prospective recipi-
ents will significantly help patient or graft survival. If 
matching could be improved. cadaver kidney survival 
would increase and the decreased amount of im-
munosuppression required for graft survival would 
reduce the morbidity of immunosuppression. The 
HLA matching as carried out today is not likely to 
accomplish these objectives. 
Kidney Preservation 
The feasibility of organ storage. even for only a few 
hours. changed the operative procedure of cadaver 
kidney transplantation from an emergency opera-
tion requiring the facilities of 2 or 3 operating 
rooms simultaneously to a procedure which could be 
carried out less hurriedly using less operating facil-
ities at one time. Organ storage also made it possible 
to carry out postmortem examination of the cadaver 
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donor prior to organ transplantation in order to dis-
cover occult infection or malignancy in the cadaver 
which might be transferred to the recipient of the or-
gan. During organ storage. histocompatibility mUlch-
ing could be completed and the recipient could have 
time for travel from home to the hospital and for op~ 
timal preparation for operation. including pre-
operative hemodialysis if necessary. 
The major characteristic of organ preservation is a 
reduction of temperatue to 4°C. Organ freezing to 
permit prolonged storage has been attempted experi-
mentally [12] but is not yet feasible without serious 
damage to the organ. Hyperbaric oxygen systems are 
not now in wide clinical use. 
The two methods of kidney storage most often 
used are infusion with and cold storage in in-
tracellular electrolyte solution [13] and continuous 
pulsatile cold perfusion with oxygenated cryoprecipi-
tated plasma [14]. Cold storage is simpler and is 
probably as effective as more complex machine per-
fusion for 18 to 24 hours [3]. For periods of preserva-
tion from .24 to 48 hours. the oxygenated machine 
preservation appears superior [15]. The use of human 
albumin rather than cryoprecipitated plasma is cur-
rently under investigation In an effort to eliminate the 
possibility of kidney damage by antibodies contained 
in the cryoprecipitated plasma. 
Although direct transfer of the kidney from a heart 
beating donor to the recipient without interval stor-
age (as is done with living related transplantation) is 
probably the optimal method of organ transfer from 
a physiological standpoint, the advantages of short-
term organ preservation seem to outweigh its disad-
vantages. 
The Transplant Operation 
The techniques of vascularization and restoration 
of urinary drainage are fairly standardized (16. 17]. 
In patients weighing more than approximately 20 kg. 
the kidney is placed in the extra peritoneal iliac fossa; 
in children weighing Jess than 20 kg. the kidney is 
placed transperitoneally in a retrocecal position. at-
taching the renal vessels to .aorta and vena cava. Vas-
cular or urinary complications are uncommon but 
not rare. I n a recent review of the experience at the 
Peter Bent Brigham Hospital in Boston. investigators 
observed arterial stenosis in 6% of cases [18], some of 
which may have been related to immunologic damage 
to the donor artery distal to the anastomosis. Renal 
vein thrombosis is observed much less frequently. 
Early urinary leak almost always requires prompt 
reoperation. Late stricture of the donor ureter has 
been seen in Jess than 5% of the Denver cases; this 
complication may be caused by periureteral adhe-
sions or by intrinsic narrowing due to devas-
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cularization. Late reconstruction by conversion of 
the ureteroneocystostomy to ureteroureterostomy 
usually provides a satisfactory result [19]. Lympho-
cele in the transplant wound occurred in 4% of Den-
ver cases in series I through 5. External drainage was 
done for all of these cases. but recently internal drain-
age via a peritoneal window has been found satisfac-
tory. eliminating the need for prolonged wound irri-
gations. 
Although the techniques of renal transplantation 
are quite straightforward. technical complications 
continue to account fOC,an important loss of grafts. 
The ACS/NIH Registry observed that about 10% of 
failed identical twin grafts. in which rejection was not 
operative. were lost from technical complications [3]. 
Immunosuppression 
Most of the complications of kidney trans-
plantation are related to the immunosuppression. 
which is required for all cases except identical twin 
transplants. Early experience at the Peter Bent Brig-~ 
ham Hospital in Boston suggested that immunosup-
pression should be used in identical twin transplants 
done for glomerulonephritis to reduce the frequency 
of recurrent glomerulonephritis in the graft [20]. 
However. 3 identical twin transplants done for glome-
rulonephritis at Denver in 1962, 1963, and 1972. 
without immunosuppression at any time. all are now 
functioning well. A fourth recipient of a twin trans-
plant. done without immunosuppression for prob-
able chronic pyelonephritis. is also functioning well 
after 10112 years. . 
The mainstays of immunosuppression have been 
corticosteroids and azathioprine. In series I in Den-
ver (1962 to 1964). on Iy azathioprine was used pro-
phylactically. reserving corticosteroids for rejection 
episodes. Corticosteroids have been used routinely since 
1964. often beginning intraoperatively. Antilympho-
cyte globulin (ALG) was added to the double-drug 
program in 1966 and continues to be used in Denver. 
but the value of this agent is still not firmly estab-
lished. It is possible that biologic differences among 
different batches of ALG may account for apparent 
variability in the effectiveness of this agent in differ-
ent centers [21]; prospective trials are currently in 
progress to attempt to finally answer the question of 
whether or not A LG combined with corticosteroids 
and azathioprine can provide better immunosuppres-
sion than corticosteroids and azathioprine alone. 
. The complications of immunosuppression include 
the complications of excess adrenal corticosteroid 
levels. hypertension. acne. obesity. diabetes mellitus. 
peptic ulcer. osteoporosis. and ocular cataract. Asep-
tic necrosis of bone has been observed in 21 % of our 
patients studied 4 to 146 months after transplantation 
lSI 
[22]. Markedly increased susceptibility to infection is 
found in immunosuppressed patients. including sus-
ceptibility to a variety of opportunistic infections 
caused by bacteria. viruses. protozoa. and fungi. Sep-
sis is the chief cause of death in kidney transplant 
patients [3]. Hyperlipidemia has been observed in 
more than 50% of dialysis and transplant patients 
[23]. Cancer occurs approximately 100 times more 
frequently in kidney transplant patients than in a 
control population. a frequency of 6% in the Denver 
patients (4). Many of these malignancies are cu-
taneous and easily treated. but there have been 5 
deaths from malignancy in the 556 patients trans-
planted between 1962 and 1975 in Denver; 4 of these 
5 deaths occurred less than 5 years after trans-
plantation. and 1 occurred later. Of the 4 earlier 
deaths. the causes were lymphoma in 3 and leukemia 
in I. 
It is urgent that a more specific and less toxic form 
of immunosuppression be developed. Immunologic 
enhancement and tolerance induction. or combina-
tions of these approaches. are being studied experi-
mentally in many centers [24. 25]. but it is not yet 
possible to control and manipulate the immune sys-
tem sufficiently well to be able to produce immuno-
logic protection or immunologic killing in a predict-
able and reliable manner. Methods of immunologic 
monitoring are being developed by means of which 
immunosuppressive medications can be adjusted ap-
propriately before the graft is rejected because of in-
adequate immunosuppression or before the patient 
dies of sepsis due to excessive immunosuppression 
[26]. 
ft is not possible to know from which direction re-
search will produce a major change in clinical im-
munosuppressive management. It seems likely that 
any major change will come from approaches that are 
not now clearly envisioned. After more than 10 years 
of speculation and after myriads of conferences about 
the clinical application of tolerance induction and 
iatrogenic enhancement. the limitations of these ap-
proaches as they have so far been tried are evident. 
Trends 
Transplanted kidneys are impermanent. Cadaver 
kidneys are less permanent than related kidneys. 
Nevertheless. kidney transplantation and retrans-
plantation. with careful individualization of care for 
each patient. are capable of providing a quality of life 
for most patients with end-stage renal disease which 
is nol possible with chronic hemodialysis. In addi-
tion. the mortality of transplantation is not different 
from the mortality of chronic hemodialysis: the 4-
year mortality of chronic dialysis in a recent National 
Dialysis Association report was 400/0 [27J. 
I 
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Transplantation and dialysis are a continuum of 
therapy for end-stage renal disease [28, 29]. As a re-
sult of the Federal HR 1 Bill passed in 1972, both 
forms of treatment are now available to almost every 
dtizen of the United States with chronic renal failure. 
It is the obligation of physicians and surgeons caring 
for these patients to use both treatments to their max-
imum advantage for each patient. 
Resume 
A Denver, Colorado, on a procede a 668 trans-
plantations renales chez 556 patients entre Novembre 
1962 et Aout 1975. L'experience de Denver a ete divi-
see en 7 periodes, selon Jes modalites de traitement 
utilisees durant ces ditferentes periodes. Les resultats 
sont demeures pratiquement les memes depuis 1966 
dans Jes cas de donneurs apparentes, et depuis 1968 
dans les cas de donneurs non-apparantes. Les resul-
tats a long terme ont ete meilleurs avec les donneurs 
apparentes qu'avec les donneurs cadaveriques. Les 
resultats obtenus chez 57 enfants entre 3 et 18 ans ont 
ete legerement superieurs a ceux obtenus chez 
I'adulte. Le plafonnement actuel des resultats est cau-
se par notre impuissance a selectionner adequatement 
les patients et les gretfons. et notre incapacite a con-
troler avec precision Ie systeme immunitaire du rece-
veur. Le rejet est responsable de la majorite des in-
succes et I'infection demeure la cause principale de 
deces. Le progres futurs dependront du developpe-
ment de moyens plus precis et moins toxiques pour 
induire la tolerance immunitaire. Cependant. meme 
avec les moyens actuels, des mi11iers de patients a 
travers Ie monde ont pu etre rehabilites. 
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INVITED COMMENTARY 
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Baltimore. Maryland. U.S.A. 
The distinguished group at the University of Colo-
rado have presented the results of 668 renal trans-
plants spanning a 14-year period. Their data are of 
great importance, for this large experience is unen-
cumbered by technical miscues so that the reasons for 
success and failure can be correlated closely with re-
jection or complications of immonosuppressive ther-
apy and can be viewed as living medical history. 
The single most important point emerging from 
this large experience is that despite 7 significant 
changes in the selection and management of patients 
for transplantation, neither transplant nor patient 
survival have changed radically. This observation is 
reAected in virtually every transplantation program. 
Thus, the feeling of optimism surrounding trans-
plantation which was present in the late sixties has 
now been replaced quite appropriately by a realiza-
tion that further progress will depend upon a break-
through in the basic science of immunology. In es-
sence, the belief was prevalent that our good results 
were on the basis of fortuitous, good, tissue matches 
which could be increased by creating large pools of 
donors and recipients: that organ preservation meth-
odology would provide the key mechanism assuring 
delivery of viable organs to perfectly matched recipi-
ents: that the elimination of blood transfusions given 
to dialysis patients would reduce pre-existing immun-
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ity which was difficult to detect by existing serological 
techniques and to suppress by drugs: and that pow-
erfuJ, new immunosuppressive modalities including 
antilymphocyte globulin would drastically reduce the 
amount of Prednisone necessary to treat threatened 
rejection thereby eliminating Prednisone-related 
complications and further extend not only successful 
renal function but rehabilitation of the transplanted 
patient. I n the ensuing years as this paper indicates, 
all of these factors breeding optimism have either 
been negated by unforeseen factors or their effects 
have been shown to be considerably I'!ss than origi-
nally anticipated. 
Perhaps the greatest disappointment has been in 
the area of histocompatibility matc,hing for unrelated 
transplantation. It is now clear that our good results 
in the past were not based on the lucky good matches. 
I n fact. the major reason why histocompatibility 
matching has proved to be unrewarding practically is 
that the obviously mismatched recipient does ex-
tremely well too frequently. Thus, in the hemo-
dialyzed patient, factors other than histocompatibil-
ity are of extraordinary importance in determining 
the outcome of the graft. Further, the discovery of B 
cell alloantigens which now appear responsible for 
the proliferative stimulus in mixed lymphocyte cul-
ture appear to be equally numerous and complex as 
the HLA-A,B,C antigen systems. Thus, when the B 
cell alloantigens are fully enumerated, a perfect 
match for all known antigens is likely to be a statis-
tical possibility alone. For these reasons more and 
more histocompatibility laboratories have concen-
trated research efforts on making disease associations 
while providing the service of family genotyping and 
the performance of antibody screening to prevent hy-
peracute rejection. Only when the suppressive aspects 
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INVITED COMMENTARY 
A:-':TII0NY P. MONACO. M,D. 
Ne ..... England Deaconess Hospital 
Bostol1, Massachusetts. U.S.A. 
The extraordinary experience of the Denver group 
in renal transplantation under the pioneering lead-
ership of Dr. Thomas Starzl has been presented, The 
data described identifies an extended experience by 
one group which re~ects with a few differences the 
national experience. The Renal Transplant Registry. 
located in the American College of Surgeons head-
quarters in Chicago a nd funded by the National I n-
stitutes of Health has compiled statistics on over . 
25.000 kidney transplants. The thirteenth and final 
report of the Registry clearly identifies the fact that 
the overall functional success of renal transplants, i.e. 
a graft functioning well enough to keep a patient alive 
and off dialysis, has not significantly changed since 
1968. ThiS is true for every type of kidney donor, 
When living-related sibling donors were analyzed, the 
one-year functional graft survival for patients done in 
the years 1968 through 1974 was 80.2, 76.5, 80.3, 
73.9, 78.6, 75.7. and 72.5% respectively. The two-, 
three-, and four-year survival rates showed a progres-
sive decline. with the five-year survival for patients 
done in 1968, 1969, and 1970 being 61.9.62.4. and 
65.9%. When living-related parental donors were 
used the results for patients done in 1968 through 
1974 were 72.4. 69,0, 75.2, 74.7. 72. 1.68.7, and 66.2%. 
The five-year survival rates were 50.5. 45.1. and 
54.7%. The slightly lower survival rates for parental 
donors reflects the theoretical advantage in closer his-
tocompatibility which sibling donors can achieve. 
Analysis of the cadaver donor results emphasized the 
significant decrease in functional graft survival 
achieved with this donor source. One-year functional 
graft survival from 1968 through 1974 was 46.4.53.7, 
55.4.53.0.50.8.49.5 and 46.3% respectively. The five-
year functional survival for patients done in 1968. 
1969. and 1970 was 28.6. 35.4 and 34.6% respectively. 
One area of significant improvement has been in 
patient survival post-transplantation. Thus. survival 
after sibling and parental transplantation has always 
been approximately 90%. However. patient one-year 
survival after cadaveric transplantation from 1968 
through 1974 has increased progressively from 58.5. 
64.5,68.5,68.7.69.8. 71.2 to 72.3% respectively. The 
decreasing mortality after cadaver transplantation is 
clearly related to a clear-cut shift toward early reduc-
tion of immunosuppression and reluctance to treat 
sustained rejection with excessive immunosuppres-
sant drugs. thus avoiding fatal infectious complica-
tions. A second area of progress has been the ext en-
R. Weil et a!.: Kidney Transplantation 
sion of renal transplantation as a form of treatment 
to patients who are obviously non-ideal or so-called 
risks. These include patients over 50. as well as those 
with diabetes and with pulmonary. coronary, liver 
and/or peripheral vascular disease. One might argue 
that maintenance of functional graft survival in the 
face of increased numbers of poor risk recipients is 
also an area of progress. Use of increased numbers of 
poor risk recipients has rendered determination of 
the effect of new forms of treatment by retrospective 
analysis difficult. Thus. the best results were obtained 
in the Denver related transplant series in Group III 
Omuran, Prednisone, "ALG-Good risk patients 
only) whereas decreased survival was achieved in 
Group IV Omuran. Prednisone. ALG-All risks). 
Survival in Group IV is about the same as Group I 
Omuran. Prednisone-No ALG-Good risks only). 
Although similar survival of Group IV and I might 
suggest no significant effect for ALG, a more plau-
sible conclusion might be that whatever salutory ef-
fect A LG had on functional graft survival was abro-
gated or obscured by the presence of high risk 
patients. Najarian et al. [I] have emphasized that all -
comparisons of treatment must take into account the 
presence of risk factors in treated and untreated 
groups with appropriate stratification of factors in 
both groups for major evaluation of treatment mo-
dalities. 
The absence of a significant improvement in func-
tional graft survival over the past 8 years raises a 
question concerning what areas of transplantation 
practice and/or immulObiology might be modified to 
improve results. Histocompatibility studies have been 
disappointing in regard to predicting and improving 
results. Knowledge of the major histocompatibility 
locus in man has grown steadily and has emphasized 
the extraordinary complexity of human histocom-
patibility antigens. Three series of serologically de-
fined (SO) antigens (H L-A. B. and C) are now identi-
fied as well as one series, HL-D. of lymphocyte de-
fined (LD). antigens. Unfortunately, in this complex 
series of antigens one or more major antigens has not 
been identified, i.e. they all seem to be of relatively 
equal importance. thus making significant histocom-
patibility matching difficult. Although extensive or-
gan sharing will aid in decreasing histocompatibility, 
it seems doubtful that drastic improvement in results 
will be obtained from improvements in histocompati-
bility matching. 
The role of presensitization in influencing func-
tional graft survival of living-related and cadaver 
grafts is somewhat controversial. Potential recipients 
are evaluated as to the presence of lymphocytotoxic 
antibody to human histocompatibility antigens by re-
action to a panel of normal lymphocytes and their de-
gree of sensitization estimated from I to 100%. Prior 
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to transplantation the recipient's serum is reacted 
with t he potential donor's antigens (usually donor 
lymphocytes or splenocytes) to assure a "negative" 
crossmatch. The Renal Transplant Registry has iden-
tified no statistical significance in one-year functional 
graft survival in living related transplants when com-
paring patients with no presensitization with those 
with 1-5% sensitization (70.7% versus 75.5%). How-
ever, when living-related recipients with greater than 
6% sensitization were considered. one-year survival 
was significantly lower. i.e. 56.6%. Similar results 
were obtained with cadaveric recipients. Thus, un-
sensitized cadaver recipients faired the same as those 
with 1-5% sensitization (47.9 and 48.9%), but cadaver 
recipients with 6% or greater sensitization had only 
40.6% survival. On the other hand. several large series 
have emphasized that no difference in survival of sen-
sitized and nonsensitized patients exists if accurate 
and elaborate crossmatch studies are performed to 
rule out the possibility of a positive crossmatch. This 
has led to the use of a number of modified crossmatch 
techniques in sensitized patients (analysis of most 
sensitized and most recent sera, prolonged cross-
match, dilutional crossmatch, antilymphocyte globu-
lin crossmatch. etc.) to detect possible sensitivity of a 
recipient to a potential donor. Also, the possibility 
that certain positive crossmatches may be due to anti-
B cell antibody (not likely to cause accelerated rejec-
tion) is currently being investigated. 
To minimize or avoid the problem of pre-
sensitization. many people had adopted a policy to 
avoid blood transfusions whenever possible and to al-
ways use frozen (leucocyte poor) blood when neces-
sary in all potential transplant recipients. There is no 
doubt that transfusions are associated with the devel-
opment of detectable cytotoxic antibody against a 
normal lymphocyte panel, although there is not nec-
essarily a direct relationship between the number of 
units transfused and the degree of sensitization gener-
ated. Nevertheless, the Renal Transplant Registry 
has identified a relatively unexpected relationship be-
tween the one-year functional graft survival of first 
cadaver transplants and the number of transfusions 
received prior to transplantation. Accepting that data 
accumulated relative to transfusion may be in-
accurate and incomplete at best, it was found that 
cadaver recipients that received no transfusions pre-
operatively had a 44.4% one-year survival while those 
that received 1-4 units. 5-9 units, or greater than 10 
units had 57.9, 60.2, and 63.8% survival, respectively. 
There was clearly a statistically significant improve-
ment in survival in any patient who was transfused 
over those who received no transfusions. There was 
no significant difference. between patients that re-
ceived 1-4 units and those that received 5-9 or 10+ 
units. Reporting was done in a manner which did not 
• 
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separate whole blood from packed and/or frozen 
cells. so a more precise anlaysis could not be done. 
Similarly analysis of patients who received whole 
blood during the transplantation operation showed 
that functional graft survival of those patients who 
received no transfusion intraoperatively was 45% at 
one-year while those who received transfusions was 
55.5%. It must be emphasized that all groups that re-
ceived transfusion prior to transplantation were 
smaller than those that received no transfusions. pre-
sumably because sensitization generated (or uncov-
ered) by transfusion prevented a negative crossmatch 
and transplantation. M any assumed that increased 
surviva I associated with transfusion pre-transplant is 
due to the development of noncytotoxic. enhancing 
antibody. This has not been substantiated. Never-
theless, the data is so suggestive that a number of 
workers have proposed a minimum uniform trans-
fusion policy to hopefully improve results. Unfortu-
nately, it is difficult to estimate how many more suc-
cessful transplants could be achieved by transfusion 
in relation to the possible negative effect of increased 
sensitization in preventing, or at least prolonging the 
wait for transplantation. If appropriate immunolo-
gical monitoring could detect or ilt~ntify the develop-
ment of the postulated enhancing antibody, rational 
pre-transplant transfusion studies could be under-
taken. This is certainly an area for intensive in-
vestigation in the next few years. 
Hopefully. efforts to avoid reliance on chronic 
nonspecific immunosuppressive therapy as illustrated 
by I muran. prednisone, and antilymphocyte globulin 
to prevent or control rejection will be expanded in the 
next few years. Several recent studies suggest that 
A LG has a beneficial effect in renal transplantation 
especially when used in good histocompatibility com-
binations, in good risk patients, in high dose, in-
travenously. for peroids of up to 28 days [2, 3,4]. Ex-
perimentally, antilymphocyte globulin seems unusu-
ally effective in producing specific al\ograft survival 
when combined with infusion of donor antigen usu-
ally in the form of cell-free antigen preparations, lym-
phocytes, splenocytes, or bone marrow cel\s [5-7]. 
This kind of approach has been tried in at least one 
cadaveric kidney recipient with results that support 
the feasibility of such a therapeutic approach [8]. Re-
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cently. evidence in our laboratory suggests that plate-
lets might be combined with a brief course of ALG 
therapy to achieve specific augmented allograft sur-
vival. The next several years may see renal trans-
plantation done utilizing a brief program of intensive 
immunosuppression followed by infusion of donor 
antigen in some form. M arrow cells. platelets, or 
whole blood are an easily acquired and expendable 
donor antigen which can be derived from living-re-
lated and cadaver donors. Immunological mon-
itoring techniques for enhancing antibody are cer-
tainly desirable but not necessarily critical to these 
trials. Transplantation is at the crossroads. Serious 
consideration should be given to carefully control\ed 
and planned clinical trials of specific donor antigen 
exposure in conjunction with renal transplantation. 
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